90 / 220
References
[1] Induction chemotherapy plus radiation compared with surgery plus radiation
in patients with advanced laryngeal cancer. The department of veterans affairs
laryngeal cancer study group. N Engl J Med. 1991;324(24):1685–90.
[2]
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845–52.
[3]
Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116(9 Pt 2 Suppl 111):1–13 .[4] Manual for Staging of Cancer. 3rd ed. Philadelphia: J.B. Lippincott Company;
1988.
[5]
Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25 (4):231–41.
[6]
Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48(1):7–16 .[7]
Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014;12 (10):1454–87.
[8]
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26(21):3582–9 .[9]
Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16(3):1141–54 .[10]
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;1999(94):496–509 .[11]
Hutcheson KA, Lewin JS, Barringer DA, et al. Late dysphagia after radiotherapy- based treatment of head and neck cancer. Cancer 2012;118(23):5793–9 .[12]
Beitler JJ, Zhang Q, Fu KK, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2014;89 (1):13–20.
M.C. Ward et al. / Oral Oncology 57 (2016) 21–26
70